A Signal Without an Answer: Ceftriaxone, Anaphylaxis, and the Limits of Public Health Investigation
- 3 September 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Abstract
No abstract availableFunding Information
- National Institutes of Health (UG3AI190386)
- National Institutes of Health (R01HG010863)
- National Institutes of Health (R01AI152183)
- National Institutes of Health (U01AI154659)
- National Institutes of Health (R13AR078623)
- National Institutes of Health (UAI109565)
- National Institutes of Health (1R21AI199163-01)
- Uptodate
- Johnson & Johnson Innovative Medicine
- Intellia
- RAPT
- Elion
- Esperion Therapeutics
- AstraZeneca
- Eli Lilly and Company
- Mirador and Verve
- LEO Fondet
- Angela Anderson Research Fund
- DRESS Syndrome Foundation
- National Health and Medical Research Council of Australia
This publication has 16 references indexed in Scilit:
- Hereditary α-tryptasemia is Associated With Anaphylaxis to Antibiotics and Monoclonal AntibodiesThe Journal of Allergy and Clinical Immunology: In Practice, 2025
- Pediatric drug-induced anaphylaxis reports in the FDA Adverse Event Reporting System (FAERS)The Journal of Allergy and Clinical Immunology: In Practice, 2024
- Non–IgE-Mediated Immediate Drug-Induced Hypersensitivity ReactionsThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- Anaphylaxis: A 2023 practice parameter updateAnnals of Allergy, Asthma & Immunology, 2023
- Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine LearningAmerican Journal of Epidemiology, 2022
- Drug allergy: A 2022 practice parameter updateJournal of Allergy and Clinical Immunology, 2022
- Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)The Journal of Allergy and Clinical Immunology: In Practice, 2020
- Post mortem tryptase: A review of literature on its use, sampling and interpretation in the investigation of fatal anaphylaxisForensic Science International, 2020
- Inappropriate ceftriaxone use in outpatient acute respiratory infection managementInfection Control & Hospital Epidemiology, 2019
- Fatal Anaphylaxis: Mortality Rate and Risk FactorsThe Journal of Allergy and Clinical Immunology: In Practice, 2017